These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 27096597)

  • 41. Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors.
    Strati P; Schlette EJ; Solis Soto LM; Duenas DE; Sivina M; Kim E; Keating MJ; Wierda WG; Ferrajoli A; Kantarjian H; Estrov Z; Jain N; Thompson PA; Wistuba II; Burger JA
    Blood; 2020 Feb; 135(7):510-513. PubMed ID: 31895947
    [No Abstract]   [Full Text] [Related]  

  • 42. Ibrutinib in the real world patient: many lights and some shades.
    Ghia P; Cuneo A
    Haematologica; 2016 Dec; 101(12):1448-1450. PubMed ID: 27903711
    [No Abstract]   [Full Text] [Related]  

  • 43. Clinical response to ibrutinib is accompanied by normalization of the T-cell environment in CLL-related autoimmune cytopenia.
    Schliffke S; Akyüz N; Ford CT; Mährle T; Thenhausen T; Krohn-Grimberghe A; Knop S; Bokemeyer C; Binder M
    Leukemia; 2016 Nov; 30(11):2232-2234. PubMed ID: 27220665
    [No Abstract]   [Full Text] [Related]  

  • 44. Targeted therapies: ibrutinib resonates with us.
    Villanueva MT
    Nat Rev Clin Oncol; 2014 Jul; 11(7):380. PubMed ID: 24935013
    [No Abstract]   [Full Text] [Related]  

  • 45. Modulated expression of adhesion, migration and activation molecules may predict the degree of response in chronic lymphocytic leukemia patients treated with ibrutinib plus rituximab.
    Peragine N; De Propris MS; Intoppa S; Milani ML; Mariglia P; Mauro FR; Raponi S; Soddu S; Cuneo A; Rigolin GM; Del Giudice I; Foà R; Guarini A
    Haematologica; 2020 Oct; 106(5):1500-1503. PubMed ID: 33054124
    [No Abstract]   [Full Text] [Related]  

  • 46. Two-drug combination benefits patients with chronic lymphocytic leukemia.
    Printz C
    Cancer; 2020 Jan; 126(1):13. PubMed ID: 31825544
    [No Abstract]   [Full Text] [Related]  

  • 47. Staphylococcal Scalded Skin Syndrome Caused by a Rare Variant of Exfoliative-toxin-A+ S. aureus in an Adult Immunocompromised Woman.
    Saluzzo S; Layer F; Stingl G; Stary G
    Acta Derm Venereol; 2018 Jan; 98(1):138-139. PubMed ID: 28853493
    [No Abstract]   [Full Text] [Related]  

  • 48. Ibrutinib may impair serological responses to influenza vaccination.
    Douglas AP; Trubiano JA; Barr I; Leung V; Slavin MA; Tam CS
    Haematologica; 2017 Oct; 102(10):e397-e399. PubMed ID: 28659336
    [No Abstract]   [Full Text] [Related]  

  • 49. Establishment of a comprehensive chronic lymphocytic leukemia clinic at a tertiary referral center in India.
    Lad DP; Tejaswi V; Malhotra P; Varma N; Sachdeva MS; Naseem S; Sreedharanunni S; Prakash G; Khadwal A; Varma S
    Blood Adv; 2018 Nov; 2(Suppl 1):33-34. PubMed ID: 30504196
    [No Abstract]   [Full Text] [Related]  

  • 50. Changes in the treatment landscape for chronic lymphoid leukemia.
    Foà R
    N Engl J Med; 2014 Jul; 371(3):273-4. PubMed ID: 25014693
    [No Abstract]   [Full Text] [Related]  

  • 51. Next-Generation Sequencing for the Identification of Targetable Molecular Alterations in Cancer.
    Dietrich MF; Collins RH; Gerber DE
    JAMA Oncol; 2016 Jan; 2(1):132-3. PubMed ID: 26426250
    [No Abstract]   [Full Text] [Related]  

  • 52. Ibrutinib: another weapon in our arsenal against lympho-proliferative disorders.
    Cabras MG; Angelucci E
    Expert Opin Pharmacother; 2015; 16(18):2715-8. PubMed ID: 26549294
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lack of adequate pneumococcal vaccination response in chronic lymphocytic leukaemia patients receiving ibrutinib.
    Andrick B; Alwhaibi A; DeRemer DL; Quershi S; Khan R; Bryan LJ; Somanath PR; Pantin J
    Br J Haematol; 2018 Sep; 182(5):712-714. PubMed ID: 28737280
    [No Abstract]   [Full Text] [Related]  

  • 54. Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia.
    Vojdeman FJ; Herman SEM; Kirkby N; Wiestner A; van T' Veer MB; Tjønnfjord GE; Itälä-Remes MA; Kimby E; Farooqui MZ; Polliack A; Wu KL; Doorduijn JK; Alemayehu WG; Wittebol S; Kozak T; Walewski J; Abrahamse-Testroote MCJ; van Oers MHJ; Geisler CH; Niemann CU
    Leuk Lymphoma; 2017 Oct; 58(10):2356-2362. PubMed ID: 28278728
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A cross-trial comparison of single-agent ibrutinib
    Tedeschi A; Greil R; Demirkan F; Robak T; Moreno C; Barr PM; Anz B; Simpson D; Gaidano G; Bairey O; Stevens D; Gill D; Flinn IW; Kipps TJ; Burger JA; Lin J; Webb T; Fedorov V; Styles L; Gribben JG
    Haematologica; 2020 Apr; 105(4):e164-e168. PubMed ID: 31413095
    [No Abstract]   [Full Text] [Related]  

  • 56. Zanubrutinib in B-cell malignancies.
    Das M
    Lancet Oncol; 2019 Sep; 20(9):e470. PubMed ID: 31378456
    [No Abstract]   [Full Text] [Related]  

  • 57. Understanding cancer cell survival is key to patient survival.
    Fegan C; Pepper C
    Lancet Oncol; 2015 Feb; 16(2):122-4. PubMed ID: 25638674
    [No Abstract]   [Full Text] [Related]  

  • 58. Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia.
    Eyre TA; Lamanna N; Roeker LE; Ujjani CS; Hill BT; Barr PM; Lansigan E; Cheson BD; Yazdy M; Allan JN; Rhodes J; Schuster SJ; Nabhan C; Skarbnik A; Leslie L; Islam P; Whitaker K; Coombs CC; Tuncer HH; Pagel JM; Jacobs R; Winter AM; Bailey N; Sitlinger A; Schuh AH; Follows G; Fox CP; Brander DM; Shadman M; Mato AR
    Haematologica; 2021 Jan; 106(1):284-287. PubMed ID: 32079693
    [No Abstract]   [Full Text] [Related]  

  • 59. Haematological cancer: Ibrutinib paves way to a brighter future in MCL.
    Killock D
    Nat Rev Clin Oncol; 2016 Feb; 13(2):65. PubMed ID: 26718106
    [No Abstract]   [Full Text] [Related]  

  • 60. [New treatment in patients with chronic lymphocytic leukemia].
    Eichhorst B; Nitschmann S
    Internist (Berl); 2020 Jul; 61(7):770-772. PubMed ID: 32179971
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.